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Abstract Oxidative stress (OXS) has been recently considered as one of anticancer strategies by taking advantage
of higher vulnerability of cancer cells (than normal cells) to OXS. In fact, the successful outcomes using OXS have
been reported in several cancer cases. A medicinal mushroom extract, PE isolated from Poria mushroom, has been
shown to have anticancer/antitumor activity, although its anticancer mechanism has not been fully understood but
may involve OXS. We investigated if PE might have anticancer effect on human bladder cancer cells through OXS
in vitro. A dose-dependent (0-200 µg/ml of PE) study was first performed to assess cell viability using MTT assay.
PE led to a significant reduction in cell viability with the IC50 (50% inhibitory concentration) of 100 µg/ml. A
possible anticancer role of OXS was then assessed by lipid peroxidation (LPO) assay. The results indicated that PE
indeed exerted ~2.1-fold greater OXS (than controls) on the cells. The anticancer mechanism of PE was further
explored, focusing on glycolysis, metabolic signaling pathways, and apoptosis. Two glycolytic parameters,
hexokinase (HK) activity and cellular ATP level, have significantly declined, suggesting the inhibition of glycolysis.
Coupled with the reduced ATP level, AMP-activated protein kinase (AMPK) was activated, while protein kinase B
(Akt) was inactivated and concomitantly mammalian target of rapamycin (mTOR) was inhibited. These results
imply the growth cessation, followed by cell death. Western blot analysis also revealed that such cell death was more
likely linked to apoptosis, indicated by the bcl-2 down-regulation and the Bax up-regulation. Therefore, PE is a
natural anticancer agent with prooxidant activity exerting OXS, which leads to inhibition of glycolysis, modulations
of metabolic signaling pathways, and ultimately apoptosis. It may have clinical implications in oral and/or
intravesical administration for a safer and better therapeutic option for bladder cancer.
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1. Introduction
Bladder cancer is the second common urologic malignancy
next to prostate cancer in the United States. Approximately
79,000 new cases and nearly 17,000 deaths of patients
with bladder cancer are estimated this year (2017) [1]. In
males, bladder cancer represents the fourth most frequent
diagnosis of new cancer annually [1]. Currently, transitional
cell carcinoma (TCC) is the most prevalent type (~90%)
of bladder cancers and approximately 80% of TCC present
superficial bladder tumor while 15% are invasive and 5%
are metastatic disease [2]. Unfortunately, regardless of
non-muscle invasive or muscle invasive cases, the current
treatment options are limited. For non-muscle invasive
bladder cancer, endoscopic transurethral resection (TUR)
is the primary modality with or without intravesical
chemotherapy or immunotherapy. However, 60%-70% of
patients will recur and ~25% will progress to muscle
invasive disease within 5 years [3], becoming untreatable
and fatal. For muscle invasive disease, chemotherapy and
surgery are the two major modalities but the prognosis is
less satisfactory because only 60% of these patients will

survive five years later, due to distant recurrence [4].
Hence, it is crucial to establish the improved modalities to
prevent multiple recurrences and progression to an advanced
invasive disease. However, over the past several decades,
only limited improvement or progress has been made.
There is the urgent need for a more effective, safer
treatment modality with few side effects.
Recently, the medicinal aspects of various natural
agents and substances have gained more public attention.
Those include herbs, mushrooms, flowers, fruits, plant
seeds, sea weeds, algae, tea, bark, shark cartilage and so
on. We were particularly interested in one well-established
medicinal mushroom called Poria mushroom and its
bioactive extract, PE. This mushroom has been used in
Traditional Chinese Medicine for 2,000 years [5] and
found to have various properties, such as antioxidant,
anticancer/antitumor, immunomodulatory, renoprotective
effects etc. [6,7,8]. As PE is a natural agent, it is
conceivable that it may have few side effects and clinical
implications in cancer treatment.
Oxidative stress (OXS), i.e. generation of reactive
oxygen species (ROS), has been known to exert adverse
effects on a variety of normal and cancer cells, injuring,
damaging and even killing them [9]. ROS include superoxide
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anion, singlet oxygen, hydroxyl radicals, hydrogen peroxide
etc., which are commonly generated through incomplete
reduction of molecular oxygen during aerobic metabolic
processes [10]. Although OXS has never been appreciated
by any means, it has been recently considered as one of
anticancer strategies by taking advantage of cancer cells
being more vulnerable to OXS than normal counterparts
[11]. The exact reason for such higher vulnerability of
cancer cells remains elusive, but at least it is believed to
be the inherent difference in tissue-specific antioxidant
system, i.e. the weakened or lack of antioxidant enzymes
in cancer cells. As a matter of fact, the successful outcomes
using OXS have been reported in several cancer cases
[11,12,13].
Taking this OXS strategy into consideration, it was of
our interest to study if PE could exert OXS on bladder
cancer cells because PE may have not only antioxidant
activity but also “prooxidant” activity (exerting OXS) like
vitamin C [14]. If PE indeed exerts OXS, it could be the
primary factor for its anticancer activity that has been
demonstrated [6]. We also explored the OXS-mediated
anticancer mechanism of PE, focusing on glycolysis,
the status of metabolic signaling pathways, and possible
induction of apoptosis. More details and interesting
findings are described and discussed herein.

2. Materials and Methods
2.1. Cell Culture
Human bladder cancer 5637 cells, obtained from the
American Type Culture Collection (ATCC; Manassas,
VA), were cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum, penicillin (100 U/ml), and
streptomycin (100 µg/ml). Routinely, culture medium was
changed every 3 to 4 days and the passage of cells was
performed weekly. PE, the bioactive extract of Poria
mushroom, was a generous gift from the manufacturer
(Mushroom Wisdom, Inc., East Rutherford, NJ). For
experiments, cells were seeded in the 6-well culture plate
at the initial cell density of 2 x 105 cells/ml and cultured
with varying concentrations of PE. Cell viability was
determined at 72 h by MTT assay.

2.2. MTT Assay (Cell Viability Test)
Cell viability was determined by the MTT (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide)
assay following the vendor’s protocol (Sigma-Aldrich, St.
Louis, MO). At the harvest time, MTT reagent (1 mg/ml)
was added to each well in the 6-well plate, followed by
3-h incubation at 37 °C. After discarding MTT reagent,
dimethyl sulfoxide (1 ml each) was added to the plate to
dissolve formazan precipitates formed. Formazan solution
(purple) was read at 595 nm on a microplate reader. Cell
viability was then expressed by the percent (%) of viable
cells relative to the control reading (100%).

2.3. Lipid Peroxidation (LPO) Assay
The severity of oxidative stress can be assessed by LPO
assay, which measures the amount of malondialdehyde

(MDA) formed, due to damage in the plasma membrane
under oxidative stress [15]. This indicates - the more
MDA formed, the greater oxidative stress. The detailed
procedures were described in the vendor’s protocol
(ABCAM, Cambridge, MA). The amount of MDA formed
was determined from the MDA standards and expressed
by µM.

2.4. Assays for Glycolytic Parameters
To assess possible effects of PE on glycolysis, two
glycolytic parameters, hexokinase (HK) activity and
cellular ATP level, were determined using the HK or ATP
Colorimetric Assay Kits (BioVision, Milpitas, CA),
respectively, following the manufacturer’s protocols.
HK Assay: Control or agents-treated cells were lysed in
HK buffer provided and supernatant (cell lysates) was
obtained by centrifugation. The NADH standards and cell
lysates (20 µg per sample) were prepared in the 96-well
plate and the reaction was started by the addition of
reaction mix (containing substrate). Immediately the plate
was placed in a microplate reader and the absorbance (OD)
changes with time were monitored at 450 nm for 20 min
with 5-min intervals. All readings were calculated and
normalized and then HK activity was expressed by the %
of sample activity relative to the controls (100%).
ATP Assay: Cells (2 x 105 cells/ml) in the 6-well plate
were first lysed in ATP assay buffer and cell lysates were
deproteinized with HClO4 (perchloric acid) and
neutralized with KOH (potassium hydroxide). The ATP
standards and samples (50 µl per sample) were prepared in
the 96-well plate and the reaction was started by the
addition of reaction mixture. The plate was incubated at
room temperature for 30 min in the dark. Absorbance (OD)
at 570 nm was read on a microplate reader and ATP
content was calculated by applying the sample readings to
the ATP standards. The ATP level was then expressed by
the % of sample readings relative to the controls (100%).

2.5. Western Blot Analysis
An equal amount of cell lysates (10 µg), obtained from
control and agent-treated cells, was first subjected to 10%
SDS gel electrophoresis and transferred to a nitrocellulose
membrane (blot). The blot was first incubated for 90 min
with the primary antibodies against three metabolic
regulators, p-AMPK, p-Akt, and p-mTOR (Santa Cruz
Biotechnology, Santa Cruz, CA), or with two apoptotic
regulators, bcl-2 and Bax (Santa Cruz Biotechnology).
After removing the primary antibodies, the blot was
incubated with the secondary antibody conjugates for 30
min. The specific immunoreactive protein bands were then
detected by chemiluminescence following the manufacturer’s
protocol (Kirkegaard and Perry Laboratories, Gaithersberg,
MD).

2.6. Statistical Analysis
All data were presented as mean ± SD (standard
deviation), and statistical differences between groups are
assessed with either the unpaired Student’s t test or oneway ANOVA analysis. Values of p <0.05 are considered
to indicate statistical significance.
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3. Results
3.1. Effects of PE on Cell Viability of Bladder
Cancer 5637 Cells
To assess anticancer effect of PE on 5637 cells, cell
viability, i.e. the % of viable cells, was determined after
they were treated with varying concentrations (0-200 µg/ml)
of PE for 72 h using MTT assay. Although PE at 50 μg/ml
had little effect, it led to a ~50% and ~90% reduction
in cell viability at 100 and 200 µg/ml, respectively, in a
dose-dependent manner (Figure 1). Thus, PE appears to
have anticancer effect, capable of significantly reducing
5637 cell viability. As PE (100 μg/ml) is proximate to its
IC50 (50% inhibitory concentration), this concentration
was then used in the rest of our study.

Figure 2. Assessment of severity of OXS. Cells were exposed to PE
(100 µg/ml) or H2O2 (50 µM) for 3 or 6 h, and the amount of MDA
formed (µM)) was assessed by LPO assay. All data are mean ± SD from
three independent experiments (*p <0.05 compared with controls)

Figure 1. Dose-dependent effect of PE on cell viability. 5637 cells were
cultured with varying concentrations of PE (0-200 µg/ml) and cell
viability was assessed in 72 h by MTT assay. Cell viability was
expressed by the percent (%) of viable cells relative to controls (100%).
The data are mean ± SD (standard deviation) from three separate
experiments (*p <0.05 compared with control)

3.2. Exertion of Oxidative Stress (OXS) by PE
Whether PE-induced cell viability reduction could be
due to OXS was examined next. Hydrogen peroxide
(H2O2, 50 µM), one of typical ROS, was also used as a
positive control for exerting OXS on cells. As OXS
usually takes place at the early phase, after cells were
briefly exposed to PE (100 µg/ml) or H2O2 (50 µM) for 3
or 6 h, they were subjected to LPO assay to determine the
severity of OXS. Compared to controls, H2O2 and PE led
to a ~3.2-fold and ~2.1-fold increase in the MDA amounts
at 6 hours, respectively (Figure 2). Thus, PE (as well as
H2O2) appears to be capable of exerting severe OXS on
5637 cells, demonstrating its prooxidant activity and
presumably accounting for the significant cell viability
reduction (Figure 1).

Figure 3. Inhibition of glycolysis by PE. Cells were treated with PE (100
µg/ml) for 72 h and subjected to HK and ATP assays separately. HK
activity and ATP level are expressed by the % relative to respective
controls (100%). The data are mean from three separate experiments (*p
<0.05 compared with control)

3.3. Effect of PE-Exerted OXS on Glycolysis
To have an insight into how PE-exerted OXS would
induce a significant cell viability reduction or to understand
the anticancer mechanism of PE, we first examined if
glycolysis could be affected/inhibited by PE because it is
the vital metabolic process required for cell proliferation
and survival [16,17]. We specifically focused on one of
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key glycolytic enzymes, hexokinase (HK), which was
involved in the irreversible committed step in glycolysis
[18]. Assuming that HK was inhibited by PE, the amount
of ATP produced or the cellular ATP level would also
decline because the sequential glycolytic pathway could
not be even initiated and completed. Accordingly, cells
were treated with PE (100 µg/ml) for 72 h and HK activity
and ATP level were assessed, as described in Materials
and Methods. Compared to controls (100%), HK activity
declined to ~50% (i.e. a ~50% activity loss) with PE
treatment (Figure 3). ATP assay revealed that the cellular
ATP level was also down to ~45% (i.e. a ~55% reduction),
due to HK inactivation. Thus, the reduction in HK and
ATP levels by PE indicates the inhibition of glycolysis,
eventually leading to the growth cessation and the cell
viability reduction.

3.4. Effects of OXS on Metabolic Signaling
Pathways
ATP (energy) reduction/depletion, due to the glycolysis
inhibition, has been shown to affect metabolic signaling
pathways, which play a pivotal role in cell proliferation
and survival [17,19]. The cells treated with/without PE for
72 h were analyzed for three key regulators, AMP-activated
protein kinase (AMPK) [20], serine/threonine protein
kinase B (Akt) [21], or mammalian target of rapamycin
(mTOR) [22] by Western blots. Such analysis revealed
that the expression of AMPK was enhanced or phosphorylated
(activated), whereas those of Akt and mTOR were
reduced or dephosphorylated (inactivated) with PE
treatment (Figure 4). Therefore, this activation of AMPK
concomitant with inactivation of Akt/mTOR by PE
suggests that 5637 cells more likely undergo cell death as
it has been shown in certain cancer cells [20,21,22].

Figure 4. Modulations of metabolic regulators by PE. Cells treated with
PE (100 µg/ml) for 72 h were analyzed for three key metabolic
regulators using Western blots. Autoradiographs of p-AMPK, p-Akt, and
p-mTOR expressed in control and PE-treated cells are shown for
comparison. Beta-actin is also shown as a loading control

3.5. Possible Induction of Apoptosis by PE
As it seems that the cell viability reduction by PE could
be primarily due to cell death, we next examined if such
cell death would be linked to apoptosis. The cells treated
with/without PE for 72 h were analyzed for two key
apoptotic regulators by Western blots. Such analysis

showed that PE treatment led to the down-regulation
(reduced expression) of anti-apoptotic bcl-2 and the upregulation (elevated expression) of pro-apoptotic Bax
(Figure 5). Such modulations of two regulators will
favor and indicate induction of apoptosis [23]. It is thus
plausible that PE-induced cell death would be rather
linked to apoptosis.

Figure 5. Induction of apoptosis. Autoradiographs of two apoptotic
regulators, bcl-2 and Bax, expressed in control and PE-treated cells are
shown following Western blot analysis

4. Discussion
Because of the ineffective therapeutic options and
unsatisfactory outcomes, bladder cancer patients and their
families are desperately seeking for a better, more effective
therapeutic modality. We have been exploring an alternative
or unconventional way to improve the therapeutic efficacy
using natural substances or products. We have come
across the bioactive mushroom extract, PE, isolated from
Poria mushroom and investigated if it might have
anticancer effect on human bladder cancer cells.
PE had a significant anticancer effect with the IC50 of
~100 μg/ml on bladder cancer 5637 cells (Figure 1). To
explore its anticancer mechanism, we examined if it
could be associated with oxidative stress (OXS). LPO
assay showed that PE did exert severe OXS on 5637 cells
as indicated by a ~2-fold increase in MDA formation (Figure
2). This finding suggests that anticancer mechanism of PE
would be substantially attributed to OXS. It has been well
known that OXS was harmful to both normal and cancer
cells but particularly cancer cells were highly or more
vulnerable to OXS [11]. Although the reason for such
discrepancy remains to be elucidated, the inherent
difference in tissue-specific antioxidant system is believed
to at least in part account for it. Based on this uncanny
nature of cancer cells, OXS is now considered as one of
anticancer strategies. Suppose relatively weak OXS were
exerted on normal and cancer cells, it could be yet severe
or strong enough to kill cancer cells (due to weaker
antioxidant enzymes) but not severe enough to even injure
normal cells (with stronger enzymes). More studies on the
status of antioxidant enzymes in bladder cancer need to be
further conducted.
Nevertheless, to elucidate how PE-exerted OXS would
lead to the cell viability reduction or even cell death, we
examined its effect on glycolysis, an essential metabolic
process. Such study showed that HK was specifically
targeted and inactivated by OXS, shutting down the
glycolytic pathway. As a result, ATP synthesis was
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also halted and its cellular level significantly declined.
These results indicate the inhibition of glycolysis and
cells may subsequently cease cell growth and result in cell
death.
As it has been shown that ATP depletion (due to the
glycolysis inhibition) would also influence metabolic
signaling pathways [17], this possibility was tested. We
found that the three key signaling regulators, AMPK, Akt,
and mTOR [20,21,22], were modulated by PE (Figure 4).
In fact, AMPK was highly phosphorylated (activated)
while Akt was dephosphorylated (inactivated) by PE.
Both AMPK and Akt must be phopsphrylated to become
active and functional [20,21]. Activation of AMPK has
been shown to be cytotoxic to a variety of cancer cells and
promote apoptosis [24], while Akt activation would
promote cell survival by inhibiting apoptosis [21,25].
Hence, AMPK and Akt will interact directly through two
opposed mechanisms [20], and activation or inhibition of
these two parameters would determine an anabolic or
catabolic process. In addition, activation of AMPK and
inhibition of Akt (as seen in this study) is known to
inactivate the master orchestrator of cell proliferation,
mTOR, which is a protein kinase working with Akt to
promote protein synthesis and cell proliferation [22]. This
is consistent with our finding that mTOR (along with
Akt) was indeed dephosphorylated or inactivated by PE
(Figure 4). Thus, AMPK activation and Akt/mTOR
inactivation induced by PE would ultimately lead to
cell death, more likely accounting for the cell viability
reduction. Lastly, whether such cell death induced by PE
would be linked to apoptosis was examined. Western blot
analysis revealed the down-regulation of bcl-2 and the
up-regulation of Bax with PE treatment (Figure 5). As
bcl-2 is anti-apoptotic but Bax is pro-apoptotic [23], this
finding is rather in support of apoptosis. Thus, PE-induced
cell death appears to follow apoptotic pathway.
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